FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder. Psychedelic and Hallucinogenic Drugs, Drug Abuse and Traffic, Regulation and Deregulation of Industry, Veterans, Post-Traumatic Stress Disorder, Therapy and Rehabilitation, Ecstasy (Drug), Mental Health and Disorders, Placebos, Drugs (Pharmaceuticals), Medicine and Health, Psychiatry and Psychiatrists, American Psychiatric Assn, Food and Drug Administration, Institute for Clinical and Economic Review, Justice Department, Lykos Therapeutics, Multidisciplinary Assn for Psychedelic Studies, your-feed-healthcare NYT > Health

​An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder. 

Leave a Reply

Your email address will not be published. Required fields are marked *